TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ACLX stock, giving a Buy rating on May 10.
Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Arcellx Inc’s recent developments and future prospects. The reiteration of promising data from the iMMagine-1 study by year-end indicates a swift completion of enrollment, which underpins confidence in the trial’s progress. Furthermore, the unveiling of the iMMagine-3 trial, which targets a larger second-line patient population and includes a more relevant standard of care control, is poised to expedite enrollment as well. This trial’s design, aiming to evaluate anito-cel against standard of care in patients with relapsed/refractory multiple myeloma who have undergone specific prior therapies, showcases a strategic approach to capturing a significant market share as therapies evolve.
In addition, the technical transfer of manufacturing to Kite, a Gilead company, is complete, mitigating a key risk factor previously held by bears of the stock. The successful transfer signals a robust partnership and manufacturing readiness for anito-cel. Additionally, the FDA’s clearance of the IND application for anito-cel, now in Kite’s hands, further solidifies the pathway toward commercialization. With the pivotal iMMagine-1 study on track for preliminary data release and a potential BLA filing, there is a clear timeline for Arcellx’s progress towards a commercial launch, which is anticipated to be in 2026. These milestones are critical indicators of the company’s trajectory and underpin Tyler Van Buren’s Buy rating for Arcellx Inc.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Arcellx Inc (ACLX) Company Description:
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
